Rohan Beckwith

Rohan Beckwith, Ph.D. is Vice President of Chemistry at Neomorph bringing over 15 years of experience in Drug Discovery, 7 in the field of targeted protein degradation. He most recently served as a Director in the Chemical Biology and Therapeutics group at the Novartis Institutes for BioMedical Research, where he was a key contributor in building a molecular glue degrader platform, from which he led efforts to establish drug discovery programs and delivered a clinical candidate. He has developed molecular glue degraders for CRBN, VHL and DCAF15 E3 ligases. In addition, Rohan has worked on over 20 research projects across various therapeutic areas, such as HECT E3 ligase inhibitors, modulators of RNA processing, Wnt pathway modulators, IAP, spinal muscular atrophy, synthetic RNA delivery, cytokine receptors, chemokine receptors, kinases). He has led multi-disciplinary teams in chemical biology and target identification efforts, as well as hit-to-lead and lead optimization. Prior to joining Novartis, Rohan conducted postdoctoral training with Prof. Huw Davies in the field of rhodium carbenoid-mediated C-H activation. He received his Ph.D. in synthetic organic chemistry from University of Nottingham, U.K. and before that his MSci. Chem from Bristol University, U.K.